Clinical Trial Update: APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) [Phase 3]

View source ↗

Summary

Phase 3 trial results for APR-246 (eprenetapopt) in combination with azacitidine for TP53-mutant myelodysplastic syndromes have been completed and the results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• APR-246 (eprenetapopt) (eprenetapopt)
• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Aprea Therapeutics | Conditions: MDS | Phase 3 | Status: COMPLETED | Results posted: 2022-07-12